Department of Clinical Pharmacy, Zaans Medical Centre, Zaandam, The Netherlands
Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, Groningen, The Netherlands.
Eur J Hosp Pharm. 2023 May;30(3):160-166. doi: 10.1136/ejhpharm-2021-002747. Epub 2021 Jul 7.
To describe the application of the model described in part A and part B of this series of articles for risk assessment (RA) and risk control (RC) of non-sterility during aseptic handling. The model was applied in nine hospital pharmacies.
The starting point was an audit of each hospital pharmacy. The determined risk reduction and remaining risks were entered into a risk assessment model. The corresponding risk prioritisation numbers (RPNs) for each source of risk were calculated and these values were summed up to a cumulative RPN. Subsequently, all hospital pharmacies started an improvement programme, using the risk assessment as input. Results of aseptic process simulation (APS) and microbiological monitoring (MM) were also collected. The participants were informed about their progress of risk reduction and results of APS and MM during the study period. At the end of the study (about 4 years after the start), a final assessment was executed by using a checklist with risk reducing measures for each source of risk. Additional risk reduction and remaining risks were put in an RA and RC template and corresponding RPN values and a new cumulative RPN were determined.
At the start of the study differences in cumulative RPN values were relatively small (from 630 to 825). At the end they were relatively great (from 230 to 725), which illustrates a different sense of urgency for reducing the risk of non-sterility. Of all the risk reducing measures, a yearly audit of all operators had the greatest impact on reducing the risk of non-sterility. Except for glove prints, there was no correlation between process improvement (lower cumulative RPN) and results of microbiological controls.
A systematic and science-based reduction of the risks of non-sterility can be done by using a checklist with risk reducing measures and an RA & RC template. Prospectively, the relevance of each risk reducing measure can be demonstrated by RPN calculations. Microbiological controls are an important part of the overall assurance of product quality. However, the results are less useful for assessing the risk of non-sterility.
描述本系列文章 A 部分和 B 部分中描述的模型在无菌操作中非无菌风险评估(RA)和风险控制(RC)中的应用。该模型应用于 9 家医院药房。
以每家医院药房的审核为起点。确定的风险降低量和剩余风险被输入风险评估模型。为每个风险源计算相应的风险优先数(RPN),并将这些值相加得到累积 RPN。随后,所有医院药房都使用风险评估作为输入启动了一个改进计划。还收集了无菌工艺模拟(APS)和微生物监测(MM)的结果。在研究期间,告知参与者他们的风险降低进度以及 APS 和 MM 的结果。在研究结束时(大约在开始后的 4 年后),使用带有每个风险源的风险降低措施的检查表执行最终评估。将额外的风险降低量和剩余风险放入 RA 和 RC 模板中,并确定相应的 RPN 值和新的累积 RPN 值。
在研究开始时,累积 RPN 值的差异相对较小(从 630 到 825)。而在结束时,差异相对较大(从 230 到 725),这说明了降低非无菌风险的紧迫性不同。在所有的风险降低措施中,每年对所有操作人员进行审核对降低非无菌风险的影响最大。除了手套印外,工艺改进(较低的累积 RPN)与微生物控制结果之间没有相关性。
通过使用带有风险降低措施的检查表和 RA & RC 模板,可以系统地、基于科学地降低非无菌风险。前瞻性地,可以通过 RPN 计算来证明每个风险降低措施的相关性。微生物控制是产品质量总体保证的重要组成部分。然而,这些结果对于评估非无菌风险的相关性较小。